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The most eﬀective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists
of intravesical instillations with the attenuated strain Bacillus Calmette-Gue´rin (the BCG vaccine). This has been performed as
an adjuvant therapeutic to transurethral resection of bladder tumour (TURBT) and mostly directed towards patients with high-
grade tumours, T1 tumours, and in situ carcinomas. However, from 20% to 40% of the patients do not respond and frequently
present tumour progression. Since BCG eﬀectiveness is unpredictable, it is important to find consistent biomarkers that can aid
either in the prediction of the outcome and/or side eﬀects development. Accordingly, we conducted a systematic critical review to
identify the most preeminent predictive molecular markers associated with BCG response. To the best of our knowledge, this is the
first review exclusively focusing on predictive biomarkers for BCG treatment outcome. Using a specific query, 1324 abstracts were
gathered, then inclusion/exclusion criteria were applied, and finally 87 manuscripts were included. Several molecules, including
CD68 and genetic polymorphisms, have been identified as promising surrogate biomarkers. Combinatory analysis of the candidate
predictive markers is a crucial step to create a predictive profile of treatment response.
1. Introduction
Thirty years have passed, and intravesical instillations with
the attenuated strain bacillus Calmette-Gue´rin (BCG) are
still considered the most eﬀective adjuvant treatment for
non-muscle invasive bladder cancer (NMIBC). Generally this
treatment is performed adjuvant to transurethral resection
of bladder tumour (TURBT) in intermediate and espe-
cially high-risk NMIBC, such as, patients with high-grade
tumours, T1 tumours, carcinoma in situ (CIS), multiple
tumours, large volume tumours, and high rate of prior
recurrence tumours [1].
Recent systematic reviews and meta-analysis have shown
that BCG therapy contributes to a significant reduction of
recurrence and disease progression for high-risk patients
and CIS when compared to TURBT alone or intravesical
chemotherapy [2–4]. However, several studies demonstrated
that from 20% to 40% of the patients fail to respond to this
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therapeutic, which may result in tumour progression [5–9].
Other important fact related with BCG treatment is that
90% of patients will experience some sort of side eﬀects
(local cystitis symptoms such dysuria, frequency alteration,
and occasional haematuria) [10, 11] and, for this reason, an
elevated number of patients did not complete the treatment
schedule [12, 13] although a significant higher withdrawal
rate of patients treated with BCG could not be demonstrated
[12–14].
Since the response to BCG is unpredictable, it is impor-
tant to find a reliable predictive biomarker and/or a marker
that could identify elevated risk groups of treatment failure
and side eﬀects development. Currently, no markers are
available to predict BCG response (neither clinicopathologic,
immunological, inflammatory nor genetic markers).
Biomarkers are defined as “a characteristic that is objec-
tively measured and evaluated as an indicator of normal
biological process, pathogenic process, or pharmacological
responses to a therapeutic intervention.” Predictive biomark-
ers will foretell how the patient is going to respond to
a given therapy. A predictive marker predicts response or
resistance to a specific therapy, whereas a prognostic marker,
as described above, predicts relapse or progression indepen-
dently of future treatment eﬀects. Many markers may have
both a prognostic and a predictive value [15].
There is some controversial among studies regarding
clinical and histopathological predictive factors; therefore,
up-to-date none of these markers have demonstrated a
reliable predictive role in BCG response, possibly because the
NMIBC population candidate for BCG therapy was already
selected for its aggressive potential.
Despite intensive research, the exact mechanisms involv-
ed in BCG therapy remain elusive. One of the major goals
for the next years is the identification of a reliable set of
immunological predictive factors, which would allow the
identification of responders and nonresponders prior to or
at the beginning of immunotherapy. In particular, this may
permit the early identification of those patients who suﬀer
the more unpleasant and potentially hazardous side eﬀects
associated with BCG therapy, enabling them to be oﬀered
alternative treatment [16].
Therefore, the purpose of this systematic review is to
conduct a critical analysis of the available literature in order
to assess molecular markers (predictive biomarkers) found to
be related with BCG treatment recurrence and progression.
To the best of our knowledge, this is the first systematic
reviews focusing only on molecular predictive biomarkers of
BCG treatment outcome.
2. Material andMethods
A systematic review was conducted through a MEDLINE
database (PubMed) search, in order to retrieve papers linking
biomarkers associated with BCG treatment outcome, avail-
able online in July 2011, using the following query: ((“Uri-
nary Bladder Neoplasms”[Mesh] OR “bladder cancer”[All
Fields] OR “superficial bladder cancer”[All Fields]) AND
(“BCG Vaccine”[Mesh] OR “bcg”[All Fields] OR “bcg treat-
ment”[All Fields] OR “BCG immunotherapy”[All Fields]
OR “BCG therapy”[All Fields] OR “intravesical therapy”[All
Fields] OR “Bacillus Calmette-Gue´rin”[All Fields])) AND
(“Neoplasm Recurrence, Local”[Mesh] OR “recurrence”[All
Fields] OR “outcome”[All Fields] OR “treatment failure”[All
Fields]).
Through this search 1324 abstracts were gathered and
then read. Inclusion/exclusion criteria were created to
retrieve only papers focusing molecular markers and BCG
immunotherapy response published before 1995. Finally, the
reference list of all selected publications and review articles
excluded was also checked for additional studies missed on
the PubMed search; therefore, two studies were included.
Finally, 87 manuscripts were included. Selected studies were
then characterized in a structured sheet, the quality assessed,
and the pooled data analyzed.
The quality of papers was also independently assessed by
two researchers (LL and LS). The quality of the studies was
assessed using an eight-item quality assessment scale, based
on STROBE Statement [17]. Each item had a score of 1, and
the mean quality score of all 87 manuscripts was 5,26/8.
Predictive factors (biomarkers) found were divided in
three major categories, such as “Tumour molecular charac-
teristics” with 34 papers that analysed a total of 40 tumour
molecular characteristics (mean quality score was 5,13/8),
“Urinary markers” 18 which were evaluated in a total of 21
published papers (mean quality score was 4.62/8), and
“Genetic Polymorphisms” with 17 papers published study-
ing 65 genetic polymorphisms in 36 genes (mean quality
score was 6.33). The outcomes evaluated were recurrence,
recurrence-free survival (RFS), progression, and progression
free Survival (PFS).
3. Results
Using the criteria defined in the material and methods
section several biomarkers related with BCG treatment have
been identified and organized according to their biological
nature. This information has been comprehensively summa-
rized in Tables 1, 2, and 3. In particular, Table 1 refers to
molecular characteristics evaluated in the tumour prior to
treatment, Table 2 refers to urinarymarkers measured during
treatment, and Table 3 compiles information about genetic
polymorphism evaluated in the context of BCG treatment
response. The most promising biomarkers are presented in
more detail the following sections.
3.1. Tumour Molecular Characteristics
3.1.1. p53. p53 is a well-known protein involved in cell cycle
and apoptosis regulation, its expression was the evaluated in
18 studies, making it the most studied molecular tumour
marker. p53 expression showed no correlation with recur-
rence rate after BCG treatment in none of the studies [18–
33]. Although higher protein expression seems to be associ-
ated with reduced time to recurrence [23, 34, 35] or progres-
sion [18, 19, 23, 26, 32, 34], but this association could not be
demonstrated by several other authors (Table 1) [22, 24–26,
28, 30, 31]. Only Saint et al. (2004) [23] and Lee (1997) [35]
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Table 1: Tumour-associated markers predicting BCG treatment outcome. The markers are ordered from the most studied to the less, and,
within each marker, the studies are ordered by quality score.
Marker Author Quality n
Treatment
scheme
Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
p53
Lopez-Beltran
et al., [34]
8/8 51 iBCG − X 0.0332/NS∗ X 0.0041/1.003
(1.002–1.074)
Park et al., [26] 7/8 61 iBCG − NS NS X 0.0495
Zlotta et al., [22] 7/8 47 iBCG None NS NS/NS∗ NS NS/NS∗
Lee et al., [35] 7/8 32 iBCG − X 0.0027/3.8
(1.3–11.4)∗
X X
Lacombe et al.,
[18]
7/8 98 iBCG − NS X X 0.0001/2.5
(1.1–5.5)∗
Palou et al., [31] 6/8 92 iBCG <PFS-M NS NS X NS/0.018∗
Esuvaranathan
et al., [30]
6/8 80 iBCG None NS NS X NS
Kyroudi-
Voulgari et al.,
[27]
6/8 66 iBCG None NS X X X
Cormio et al.,
[32]
5/8 27 mBCG − NS NS NS 0.06
Saint et al., [23] 5/8 102 iBCG/mBCG − NS 0.03/0.15
(0.06–0.42)∗
0.001 <0.0001
Peyromaure
et al., [24]
5/8 29 iBCG None NS NS NS NS
Caliskan and
Tu¨rkeri [19]
5/8 30 iBCG >Prog NS/NSa X NS/NSa 0.04
Pages et al., [25] 4/8 43 iBCG None NS NS X X
Okamura et al.,
[20]
4/8 38 mBCG None NS X X X
Moyano Calvo
et al., [29]
3/8 51 iBCG None NS X X X
Moyano Calvo
et al., [33]
3/8 71 iBCG None NS X NS X
Lebret et al.,
[21]
3/8 35 iBCG None NS X X X
Serdar et al.,
[28]
1/8 24 iBCG None NS NS X X
Ki-67
Lopez-Beltran
et al., [34]
8/8 51 iBCG − X 0.0034/NS∗ X 0.0163/NS∗
Park et al., [26] 7/8 61 iBCG − NS NS X NS
>25% Zlotta et al., [22] 7/8 47 iBCG − NS 0.02/NS∗ NS NS/NS∗
Lee et al., [35] 7/8 32 iBCG − 0.0413 0.0164/NS∗ X X
Palou et al., [31] 6/8 92 iBCG >Rec 0.015 NS X NS/NS∗
Kyroudi-
Voulgari et al.,
[27]
6/8 66 iBCG − <0.05 X X X
Blanchet et al.,
[38]
5/8 57 iBCG − X NS/NS∗ X 0.0001/4.61 (P <
0.04)
>20%
Lebret et al.,
[37]
5/8 25 iBCG − 0.03 X X X
Moyano Calvo
et al., [33]
3/8 71 iBCG None NS X NS X
Moyano Calvo
et al., [29]
3/8 51 iBCG None NS X X X
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Table 1: Continued.
Marker Author Quality n
Treatment
scheme Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
pRB
Park et al., [26] 7/8 61 iBCG − NS NS X NS
+
Esuvaranathan
et al., [30]
6/8 80 iBCG None NS NS X NS
Altered exp
Cormio et al.,
[39]
5/8 27 mBCG − X 0.037 X 0.018
CD68
High TAM Ayari et al., [41] 6/8 46 iBCG/mBCG − X 0.093/3.81
(1.32–11)b
X X
High TAM
Takayama et al.,
[42]
6/8 411 iBCG − 0.0023 0.0002/1.7
(1.48–5.03)c
X X
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
c-erbB2 Lee et al., [35] 7/8 32 iBCG None X NS/NS∗ X X
Janane et al.,
[43]
5/8 84 iBCG − X <0.01 X X
Morgan et al.,
[95]
5/8 82 iBCG None NS X X X
E-Cadherin
Moyano Calvo
et al., [29]
3/8 51 iBCG None NS X X X
Serdar et al.,
[28]
1/8 24 iBCG None NS NS X X
bcl-2 Lee et al., [35] 7/8 32 iBCG − X 0.0112/NS∗ X X
Okamura et al.,
[20]
4/8 38 mBCG + 0.044 X X X
p21
Lopez-Beltran
et al., [34]
8/8 51 iBCG None X NS/NS∗ X NS/NS∗
>10% Zlotta et al., [22] 7/8 47 iBCG − NS 0.02/NS∗ NS NS/NS∗
p27
Lopez-Beltran et
al., [34]
8/8 51 iBCG + X
0.0005/0.997
(0.995–0.999)∗
X 0.0161/NS∗
Park et al., [26] 7/8 61 iBCG − NS NS X NS
Cyclin D1
Lopez-Beltran
et al., [34]
8/8 51 iBCG − X 0.0103/NS∗ X <0.0001/1.009
(1.002–1.074)∗
Cyclin D3
Lopez-Beltran
et al., [34]
8/8 51 iBCG − X 0.0332/NS X 0.0041/1.003
(1.002–1.074)∗
PTEN Park et al., [26] 7/8 61 iBCG − NS NS X NS
FGFR3 Park et al., [26] 7/8 61 iBCG − NS NS X NS
CD9 Park et al., [26] 7/8 61 iBCG − NS NS X NS
hTERT
Pre-treat
>75%
Zachos, [96] 7/8 30 iBCG − X 0.05/NSc NS/NSc X
c-myc Lee et al., [35] 7/8 32 iBCG None X NS/NS∗ X X
Cathepsin D Lee et al., [35] 7/8 32 iBCG − X 0.0235/NS∗ X X
CD83
High
CD83+
Ayari et al., [41] 6/8 53 mBCG − X 0.0001/9.81
(1.12–85.7)d
X X
Ezrin Palou et al., [31] 6/8 92 iBCG − 0.041 0.06 X 0.009/0.031∗
NKp30 Yutkin, [46] 6/8 17 iBCG <Rec 0.0026 X X X
NKp44 Yutkin, [46] 6/8 17 iBCG <Rec 0.027 X X X
NKp46 Yutkin, [46] 6/8 17 iBCG <Rec 0.044 X X X
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Table 1: Continued.
Marker Author Quality n
Treatment
scheme Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
PD-L1
Inman et al.,
[97]
5/8 44 iBCG/mBCG None NS X X X
CD25
Honda et al.,
[98]
5/8 16 iBCG None NS X X X
Cox-2 Kim et al., [45] 5/8 37 iBCG − X 0.0493 X 0.0272
VEGF
Morgan et al.,
[95]
5/8 82 iBCG None NS X X X
TCR γ/δ
Honda et al.,
[98]
5/8 16 iBCG None NS X X X
HSP60
Lebret et al.,
[47]
4/8 33 iBCG None NS X NS X
HSP90
Loss exp
Lebret et al.,
[47]
4/8 33 iBCG − 0.0001 X 0.0001 X
CD4
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
CD8
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
HLA class I
Kitamura et al.,
[48]
4/8 30 iBCG + X
0.0394/0.06
(0.01–0.4)
X X
CD20
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
TIA-1
Kitamura et al.,
[48]
4/8 30 iBCG None X 0.0393/NS∗ X X
S-100
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
FOXP3
Kitamura et al.,
[48]
4/8 30 iBCG None X NS/NS∗ X X
PCNA
Okamura et al.,
[20]
4/8 38 mBCG None NS X X X
HSP65
Ardelt et al.,
[99]
3/8 16 mBCG None NS X X X
B-Catenin
Moyano Calvo
et al., [29]
3/8 51 iBCG + <0.05 X X X
−: negative impact, marker associated with a poor BCG response.
+: positive impact, marker associated to a better BCG response.
Rec: recurrence; P value for recurrence.
RFS: recurrence-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
Prog: progression; P value for progression.
PFS: progression-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
iBCG: induction BCG scheme only.
mBCG: maintenance BCG scheme.
NS: no statistical significance.
X: not evaluated.
∗all analysed variables (independent prognostic factor).
aadjusted for grade and stage.
badjusted for age, gender, T stage and number of mBCG instillations.
cadjusted for age and gender.
dadjusted for age, gender, T stage.
1only CIS patients.
found that p53 could be an independent prognostic factor,
but with opposite results. TP53 gene mutation was also
associated with higher recurrence rate [36]. It seems that p53
could not be a suitable predictive marker, since the majority
of the studies could not corroborate these findings.
3.1.2. Ki-67. Ki-67 is a nuclear protein for cellular prolifera-
tion, used as a marker of cell proliferation index. Higher ki-
67 expression seems to be associated with recurrence after
BCG [27, 31, 35, 37] and with lower time to recurrence [22,
34, 35]. Still, multivariate analysis failed to prove its value as
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Table 2: Urinary markers predicting BCG treatment outcome. The markers are ordered from the most studied to the less, and, within each
marker, the studies are ordered by quality score.
Marker Author Quality n
Treatment
scheme Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
IL-8
Sagnak et al.,
[54]
6/8 41 iBCG − X 0.006/2.98
(1.02–8.72)a
X X
Kumar et al.,
[57]
5/8 26 iBCG + 0.001 X X X
Sanchez-
Carbayo et al.,
[58]
5/8 15 iBCG None NS X X X
Jackson et al.,
[60]
5/8 34 iBCG None NS/NS∗ X X X
Rabinowitzir et
al., [62]
5/8 46 iBCG None NS X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
Watanabe et al.,
[56]
4/8 20 iBCG + <0.05 0.013/NS∗ X X
Thalmann et al.,
[59]
4/8 17 iBCG + 0.0209 X X X
Thalmann et al.,
[61]
4/8 20 iBCG + 0.0002 X X X
IL2 Saint et al., [64] 5/8 37 iBCG + X 0.0009 X NS
Sanchez-
Carbayo et al.,
[58]
5/8 15 iBCG + 0.041 X X X
Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
De Reijke et al.,
[66]
5/8 23 iBCG + 0.003 X X X
Saint et al., [63] 4/8 39 mBCG + X 0.01 X 0.01
Watanabe et al.,
[56]
4/8 20 iBCG + <0.01
0.0003/0.37
(0.03–0.895)∗
X X
Saint et al., [65] 4/8 19 iBCG + iBCG None/+
NS/
<0.05
X X X
IFN-γ Saint et al., [64] 5/8 37 iBCG None X NS X NS
Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
Watanabe et al.,
[56]
4/8 20 iBCG None NS NS/NS∗ X X
Saint et al., [65] 4/8 19 iBCG + iBCG +/None
<0.05/
NS
X X X
TNF-α
Sanchez-
Carbayo et al.,
[58]
5/8 15 iBCG None NS X X X
Jackson, [60] 5/8 34 iBCG +
NS/
<0.05∗
X X X
De Reijke et al.,
[66]
5/8 23 iBCG + 0.025 X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
Watanabe et al.,
[56]
4/8 20 iBCG + <0.05 0.012/NS∗ X X
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Table 2: Continued.
Marker Author Quality n
Treatment
scheme Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
IL-10 Saint et al., [64] 5/8 37 iBCG None X NS X NS
Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
Saint et al., [63] 4/8 39 mBCG None X NS X NS
Watanabe et al.,
[56]
4/8 20 iBCG + <0.01 0.009/NS∗ X X
Saint et al., [65] 4/8 19 iBCG + iBCG None NS X X X
IL-6
Sanchez-
Carbayo et al.,
[58]
5/8 15 iBCG None NS X X X
Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
De Reijke et al.,
[66]
5/8 23 iBCG + 0.04 X X X
Watanabe et al.,
[56]
4/8 20 iBCG + <0.05 0.023/NS∗ X X
Urovysion
(FISH)
Whitson et al.,
[100]
6/8 48 mBCG − X <0.01/6.7
(2.1–22.1)∗
X X
+posttreat
Savic et al.,
[101]
5/8 68 iBCG − X <0.001/5.6
(2.5–12.2)∗
X X
Mengual, [102] 5/8 65 iBCG − X 0.015/2.7(1.18–
6.15)∗
X X
+pretreat
Kipp et al.,
[103]
5/8 37 iBCG − X NS/3.3(1.3–8.5)∗ X NS/NS∗
+posttreat − X <0.001/4.6
(1.9–11.1)
X
0.001/9.4
(1.9–45.3)
IL-12 Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
Watanabe et al.,
[56]
4/8 20 iBCG None NS NS/NS∗ X X
IL-1β
De Reijke et al.,
[66]
5/8 23 iBCG None NS X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
Watanabe et al.,
[56]
4/8 20 iBCG None NS NS/NS∗ X X
GM-CSF Jackson, [60] 5/8 34 iBCG − <0.05/
<0.05∗
X X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
WBC
Saint et al.,
[104]
5/8 72 mBCG + X 0.009 X X
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
G-CSF
Shintani et al.,
[55]
4/8 20 iBCG None NS X X X
FN
Danis¸man et al.,
[69]
5/8 38 iBCG None NS X X X
IL-4 Jackson, [60] 5/8 34 iBCG None NS/NS∗ X X X
sICAM-1 Jackson, [60] 5/8 34 iBCG +
NS/
<0.05∗
X X X
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Table 2: Continued.
Marker Author Quality n
Treatment
scheme Impact
Outcome
Rec(P)
RFS
(P/HR (95% CI))
Prog(P)
PFS
(P/HR (95% CI))
sCD14 Jackson, [60] 5/8 34 iBCG − NS/
<0.05∗
X X X
Survivin Hausladen, [68] 4/8 23 iBCG − <0.05 X X X
IL-18
Thalmann et al.,
[59]
4/8 17 iBCG + 0.0464 X X X
iBCG: induction BCG scheme only.
mBCG: maintenance BCG scheme.
−: negative impact, marker associated with a poor BCG response.
+: positive impact, marker associated to a better BCG response.
Rec: recurrence; P value for recurrence.
RFS: recurrence-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
Prog: progression; P value for progression.
PFS: progression-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
NS: no statistical significance.
X: not evaluated.
∗all analysed variables (indepent prognostic factor).
aadjusted for BCG-related complications, tumour stage, and grade.
an independent predictive marker [22, 34, 35]. Furthermore,
Lopez-Beltran et al. [34] and Blanchet et al. [38] found that
the Ki-67 expression could be associated with lower PFS in
univariate analysis and multivariate analysis, respectively. At
the moment, Ki-67 could not be used as predictive marker
of BCG response, due to the fact that half of the studies
regarding this marker did not find any association with BCG
treatment response.
3.1.3. (Retinoblastoma Protein) pRB. Only three studies eval-
uated the tumor suppressor protein, pRB; namely, Cormio
and colleagues in 2010 [39] assessed pRB-altered expression
in only 27 patients treated with a full maintenance BCG
treatment schedule (mBCG) and found it associated with
RFS and PFS. Park et al. [26] and Esuvaranathan et al.
[30] evaluate pRB in patients subjected only to induction
schedule with BCG (iBCG) and did not find any relationship
with protein-positive staining and recurrence, RFS or PFS.
These findings suggest that this marker could be a possible
indicator of BCG response in patients treated with mBCG
although more studies need to be performed in order to
clarify this association.
3.1.4. CD68 (Marker of TAMs Presence). Tumour-associated
Macrophages (TAMs) may have a dual role in cancer. They
could be involved in tumor-cell elimination or can stimulate
tumor-cell proliferation, promote angiogenesis, and favour
invasion and metastasis [40]. CD68 is a glycoprotein, and
its expression allows identifying macrophages.In 2009 Ayari
et al. [41] found that a higher TAM count in peritumoural
region was associated with lower RFS and with a high
risk of BCG treatment failure. The same was reported for
CIS tumors treated with BCG by Takayama [42]. This
marker could be a suitable biomarker for predicting BCG
treatment response although more studies are necessary to
confirm these findings and to prove TAMs influence in BCG
immunotherapy response.
3.1.5. Other Intracellular Markers. c-erB2 is a proto-onco-
gene, member of the epidermal growth factor receptor
(EGFR/ErbB) family. Janane et al. (2011) [43] found that
c-erB2 expression was associated with lower RFS after
BCG treatment. Apoptosis regulator protein, bcl-2, was also
studied, but doubts persist about its predictive value of
BCG treatment outcome due to conflicting results found by
Okamura et al. [20] and Lee et al. [35]. Some authors eval-
uated the role cyclin-dependent kinase inhibitors, p21 and
27, as predictors of BCG response. Zlotta et al. [22] found
that higher p21 expression was associated with decreased
RFS in univariate analysis, and Lopez-Beltran and colleagues
[34] found that higher expression of p27 was associated
with decreased RFS and PFS. These markers are regarded
unsuitable candidates to predict BCG treatment response,
due to the lack of consistency of the so far presented results
(see Table 1). Proteins involved in cell cycle regulation, such
as Cyclin D1 and D3, were found to be slightly associated to
reduced RFS and PFS [34] although these results were limited
to one study, thus needing further investigation. On the other
hand, Cyclin D3 gene amplification was also associated with
decreased RFS as shown by Lopez-Beltran et al. [44].
3.1.6. Other Protein Markers. Other 30 diﬀerent markers
were also studied, as shown in Table 1. All of them
were evaluated only in one single study. One of the most
promising markers is ezrin, a cytoplasmic peripheral mem-
brane protein involved in cell surface structure adhesion,
migration, and organization. Palou et al. [31] never shown
that this protein was associated to higher recurrence rate,
reduced RFS and PFS. Other markers have shown some
potential as predictive marker. Cox-2, which promotes the
conversion of arachidonic acid to prostaglandins, could also
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Table 3: Genetic polymorphisms associated to BCG outcome. The markers are ordered from the most studied to the less, and, within each
marker, the studies are ordered by quality score.
Marker Author Quality n Treatment scheme Impact RFS (P/HR (95% CI))
NRAMP
D543N GG Chiong et al., [73] 6/8 99 mBCG − 0.033/4.6 (1.4–15.2)a
D543N GA Decobert et al., [74] 6/8 67 iBCG + mBCG − 0.0271/5.74 (2.4–13.8)b
(GT)n allele 3 Chiong et al., [73] 6/8 99 mBCG − NS/24.8 (3.08–199.9)a
Decobert et al., [74] 6/8 67 iBCG + mBCG None NS/NSb
469 + 14 G/C Decobert et al., [74] 6/8 67 iBCG + mBCG None NS/NSb
274 C/T Decobert et al., [74] 6/8 67 iBCG + mBCG None NS/NSb
1465 − 85 G/A Decobert et al., [74] 6/8 67 iBCG + mBCG None NS/NSb
XPA 5′UTR A/G Gu et al., [75] 6/8 112 iBCG + mBCG − 0.078
XPC
Lys 939 Gln Gangwar et al., [76] 7/8 77 iBCG − 0.044/3.98 (1.02–10.7)∗
Gu et al., [75] 6/8 112 iBCG + mBCG None NS
PAT ins/del Gangwar et al., [76] 7/8 77 iBCG None NS∗
Gu et al., [75] 6/8 112 iBCG + mBCG None NS
Ala 499 Val Gu et al., [75] 6/8 112 iBCG + mBCG None NS
XPD
Asp312Asn Gu et al., [75] 6/8 112 iBCG + mBCG None NS
Lys751Gln Gu et al., [75] 6/8 112 iBCG + mBCG None NS
XPG Asp1104His Gu et al., [75] 6/8 112 iBCG + mBCG None NS
IL8
−251 T/A Ahirwar et al., [81] 7/8 71 iBCG + <0.001/0.12 (0.04–0.38)c
Leibovici, [86] 6/8 123 iBCG/mBCG None NSd/NSd
+678 C/T Ahirwar et al., [81] 7/8 71 iBCG None NSc
TNFA
−1031 T/C Ahirwar et al., [85] 7/8 73 iBCG + 0.024/0.38 (0.14–0.98)c
−857 C/T Ahirwar et al., [85] 7/8 73 iBCG None NSc
−863 C/A Ahirwar et al., [85] 7/8 73 iBCG None NSc
−308 G/A Ahirwar et al., [84] 6/8 69 iBCG None NSe
Leibovici, [86] 6/8 123 iBCG/mBCG None NSd/NSd
IL6 −174 G/C Ahirwar et al., [84] 6/8 69 iBCG + 0.021/0.298 (0.09–091)e
Leibovici, [86] 6/8 123 iBCG/mBCG − NSd/4.6 (1.24–17)d
hGPX Pro198Leu C/T Chiong et al., 2010 [73] 6/8 99 mBCG None NSa
MMP1
−519 A/G Srivastava, [90] 6/8 iBCG None NS
−1607 1G/2G Srivastava, [90] 6/8 iBCG + 0,030
MMP2
−735 C/T Srivastava, [91] 7/8 78 iBCG None NSc
−1306 C/T Srivastava, [91] 7/8 78 iBCG − 0.039/2.06 (1.01–4.18)c
MMP3
−1171 5A/6A Srivastava, [92] 6/8 78 iBCG − 0.025/2.01 (0.98–4.12)c
Rs6796720 G/A Srivastava, [92] 6/8 78 iBCG None NSc
Rs 520540 A/G Srivastava, [92] 6/8 78 iBCG None NSc
MMP7 −181 A/G Srivastava, [90] 6/8 iBCG None NS
MMP8 +799 C/T Srivastava, [91] 7/8 78 iBCG None NSc
MMP9
Q279R A/G Srivastava, [92] 6/8 78 iBCG None NSc
P574R G/C Srivastava, [92] 6/8 78 iBCG None NSc
R668Q G/A Srivastava, [92] 6/8 78 iBCG None NSc
ERCC1 3′UTR G/T Gu et al., [75] 6/8 112 iBCG/mBCG None NS
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Table 3: Continued.
Marker Author Quality n Treatment scheme Impact RFS (P/HR (95% CI))
ERCC2
Asp312Asn G/A Gangwar et al., [77] 6/8 74 iBCG − 0.005/3.07 (1.22–7.68)c
Lys751Gln A/C Gangwar et al., [77] 6/8 74 iBCG None NSc
ERCC6
Met1097Val A/G Gu et al., [75] 6/8 112 iBCG/mBCG − 0.022
Arg1230Pro G/C Gu et al., [75] 6/8 112 iBCG/mBCG None NS
APEX1 Asp148Glu T/G Gangwar et al., [77] 6/8 74 iBCG None NSc
COX2
−1290 A/G Gangwar et al., [83] 6/8 79 iBCG None NSe
−1195 G/A Gangwar et al., [83] 6/8 79 iBCG None NSe
−765 G/C Gangwar et al., [83] 6/8 79 iBCG − 2.43 (0.34–1.85)e
+8473 T/C Gangwar et al., [83] 6/8 79 iBCG None NSe
IFNA LOH Cai, [82] 7/8 77 mBCG − <0.0001/4.09 (2.59–6.28)∗
IFNG +874 T/A Ahirwar et al., [80] 7/8 73 iBCG − 2.24 (1.06–5.80)c
NFkB ATTG Ins/Del Ahirwar et al., [81] 7/8 71 iBCG − 0.031/2.53 (1.00–6.36)c
CASP9
−1263 A/G Gangwar et al., [88] 7/8 79 iBCG + 0.024/0.27 (0.15–0.62)c
−293 Ins/Del Gangwar et al., [88] 7/8 79 iBCG None NSc
CASP8 −6N Ins/Del Gangwar et al., [88] 7/8 79 iBCG None NSc
IL4 VNTR Ahirwar et al., [84] 6/8 69 iBCG None NSe
IL1B −511 C/T Ahirwar et al., [80] 7/8 73 iBCG None NSc
IL1RN VNTR Ahirwar et al., [80] 7/8 73 iBCG None NSc
TGFB1 +28 C/T Ahirwar et al., [80] 7/8 73 iBCG + 0.37 (0.14–0.98)c
MDM2 +309 G/T Gangwar et al., [89] 6/8 79 iBCG + 0.25 (0.08–0.80)c
CCDN1 +870G/A Gangwar et al., [89] 6/8 79 iBCG None NSc
FAS −670A/G Gangwar et al., [89] 6/8 79 iBCG None NSc
XRCC1
Arg194Trp C/T Mittal et al., [78] 5/8 61 iBCG None NS∗
Arg280His G/A Mittal et al., [78] 5/8 61 iBCG None NS∗
Arg399Gln G/A Mittal et al., [78] 5/8 61 iBCG − 0.004/5.05 (1.34–19.01)∗
XRCC3
+18067 C/T Mittal et al., [79] 7/8 73 iBCG None NSc
+17893 A/G Mittal et al., [79] 7/8 73 iBCG None NSc
XRCC4
+1394 G/T Mittal et al., [79] 7/8 73 iBCG None NSc
Intron 3 (rs2836007) Mittal et al., [79] 7/8 73 iBCG None NSc
Intron 7 (rs2836317) Mittal et al., [79] 7/8 73 iBCG None NSc
Intron 7 (rs1805377) Mittal et al., [79] 7/8 73 iBCG None NSc
PPARG Pro12Ala Leibovici, [86] 6/8 123 iBCG/mBCG None NSd/NSd
GLI3
rs6463089 G/A Chen et al., [93] 7/8 204 iBCG + mBCG − 2.40 (1.50–3.84)∗
rs3801192 G/A Chen et al., [93] 7/8 204 iBCG + mBCG − 2.54 (1.47–4.39)∗
iBCG: induction BCG scheme only.
mBCG: maintenance BCG scheme.
−: negative impact, marker associated with a poor BCG response.
+: positive impact, marker associated to a better BCG response.
RFS: recurrence-free survival; P value for log-rank test/HR: hazard ratio from Cox regression; (95% Cl): 95% confidence interval.
NS: no statistical significance.
∗all analysed variables (indepent prognostic factor).
aadjusted for age, gender, ethnicity, tumour stage and grade, smoking history, and BCG vaccination status.
badjusted for Cis background, multifocality, and mBCG treatment.
cadjusted for age, gender, and smoking history.
dadjusted for age, gender, smoking history, and grade.
eadjusted for age and gender.
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help to predict early recurrence and progression [45]. Yutkin
et al. [46] studied natural killer cells cytotoxic receptors and
described that expression of Nkp family proteins, 30, 44, and
46, were associated with less recurrence after treatment. Heat
shock protein 90 (HSP90) loss of expression was associated
to higher recurrence and progression rates [47]. These may
therefore be candidate markers to predict recurrence after
BCG treatment.
All of these markers, and others [41, 48] need further
investigation once they were only evaluated in one study and
with samples rounding 30 or 50 patients, almost only treated
with iBCG schedule.
3.1.7. Genetic Markers Evaluated on Tumour
Gene Expression. Other markers have been studied in tum-
our biopsies, such as genetic markers (not shown in Table 1).
Gazzaniga et al. (2009) [49] evaluated α5β1 integrin gene
expression (the integrin involved in BCG attachment and
internalization into cells) in the tumours of 11 patients
treated with BCG and found that lower α5β1 expression was
associated with recurrence [49].
Videira et al. [50] evaluated the expression of 10 immu-
nological genes involved in antigen presentation (CD1 and
MHC-I) and chemokines (MIP-1, MCP-1/2, IP10 andMIG).
This study showed higher mRNA levels of MHC-I for
tumours that will not relapse after treatment and tumours
that will recur have lower expression of CD1c, CD1e and
MCP-1. They also found higher expression of CD1a, CD1b,
CD1c, CD1e, MHC-I, MIG, and IP10 in biopsies after
treatment in the group of patient without recurrence when
compared with the recurrence group [50].
Kim and colleagues [51] performed a microarray analysis
in tumours from 80 patients treated with BCG, and they
could identify a subset of genes that individually are asso-
ciated with reduced RFS and PFS. When evaluated together,
the “poor predictive signature” presented a 3.38 higher risk
of recurrence or 10,49 higher risk of progression after BCG
treatment [51].
These findings demonstrate that evaluation of gene ex-
pression patterns in tumours prior to treatment has the
potential to undisclose a new subset of biomarkers capable
predicting BCG treatment response. More studies are needed
to validate these markers and possible find new ones.
Gene Methylation. Alvarez-Mu´gica et al. [52] studied the
methylation status of myopodin gene (involved in actin-
bundling activity) and found that this event is associated
with reduced RFS [52]. Recently, Agundez and colleagues
[53] evaluated methylation status in 25 tumour suppressor
genes. It was found that diﬀerential methylation for several
genes had an impact BCG treatment outcome. Therefore,
methylation of PAX6 gene is associated with lower RFS [53].
However, unmethylated MSH6, RB1, THBS1, PYCARD,
TP73, ESR1, andGATA5 genes are associated with higher PFS
[53]. This new approach could contribute to establish new
candidate predictive biomarkers of BCG treatment response.
3.2. Urinary Markers
3.2.1. IL-8 (Major Mediators of the Inflammatory Response).
Urinary levels of the chemokine IL-8, a potent chemoattrac-
tant of neutrophils and macrophages, could be a potential
biomarker of BCG treatment response. Several authors
found that higher IL-8 levels are significantly associated with
a better treatment outcome [54–62]. Only Sagnak et al.
(2009) [54] andWatanabe et al. (2003) [56] found that lower
levels of IL-8 are a slightly associated with reduced RFS.
These studies presented levels measured in diﬀerent time
points of BCG treatment and its predictive value was accessed
with diﬀerent cutoﬀ values; therefore, it is imperative to
evaluate the same cutoﬀ values in larger sets of samples.
3.2.2. Interleukin 2 (IL-2). IL-2 is a Th1 subset cytokine, in-
volved in cytotoxic T lymphocyte expansion (cytotoxic T
lymphocytes and natural killer cells) and macrophage acti-
vation. IL-2 urinary levels were extensively studied [56, 58,
60, 63–66], and higher IL-2 urinary levels were appointed
to be a good predictive marker of recurrence [56, 58, 60,
65, 66] and higher RFS [56, 63, 64]. Saint also found
that lower or absent levels of IL-2 were associated with
shorter PFS in mBCG-treated patients but not in iBCG
[63, 64]. IL-2 urinary levels are themost promising predictive
biomarker of BCG treatment response; however, it could
only be measured during treatment and could not be used in
treatment definition. These results highlight the key role of
IL-2 in BCG treatment response; therefore, it is important to
evaluate why nonresponders have lower IL-2 levels, in order
to establish IL-2-related biomarkers that could predict BCG
response prior to treatment.
3.2.3. Other Urinary Cytokines. Other urinary cytokines have
demonstrated to have potential as predictive biomarkers, yet
some need further investigation. Tumour necrosis factor α
(TNF-α), whose primary role is the regulation of immune
cells, and its urinary levels have been evaluated during the
course of BCG treatment in several studies. It was found that
higher TNF-α levels are associated with a higher response
rate [55, 56, 58, 60, 66]. Watanabe et al. (2003) [56],
also demonstrated that higher levels of this molecule are
associated with better RFS.
IL-6 is an interleukin that acts as both a proinflammatory
and anti-inflammatory cytokine. It is secreted by T cells and
macrophages to stimulate immune response. Higher IL-6
urinary levels during BCG treatment were associated with
lower recurrence rates and higher RFS [56, 58, 60, 66].
IL-18 is a proinflammatory cytokine, produced by
macrophages, and induces cell-mediated immunity. Lower
urinary levels of this protein have been found within the first
12 h after BCG in nonresponders to BCG treatment [59].
Although this cytokine was only evaluated in 17 patients,
others authors suggest that IL-18 has a key role in the
mechanism of intravesical immunotherapy with BCG [67].
IFN-γ is involved in macrophage activation and Th1
diﬀerentiation, and higher urinary levels were associated
with a good treatment response in a first course of iBCG
12 Advances in Urology
[65], yet other authors could not confirm this association
[55, 56, 60, 64].
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) is a cytokine that functions as a white blood cell
growth factor. GM-CSF stimulates stem cells to produce
granulocytes (neutrophils, eosinophils, and basophils) and
monocytes. GM-CSF levels were evaluated in 2 papers
[55, 60]; only Jackson et al. (1998) [60] found that higher
levels of these molecule were associated with reduced
recurrence rate.
Somehow, all of these cytokine are associated with treat-
ment response; however, their predictive value fails to be con-
sistent among the studies. Once more, important molecules
involved in BCGmechanism of action have been highlighted;
hence, it is essential to explore other biomarkers related to
these cytokine urinary levels variability.
3.2.4. Other Markers. Other 7 markers were evaluated in 4
papers, only regarding recurrence rate [60, 68, 69]. Higher
levels of survivin (member of the inhibitor of apoptosis fam-
ily) and soluble CD14 (acts as a coreceptor in recognize
pathogen-associated molecular patterns) were present in the
recurrence group [60, 68]. The soluble intercellular adhesion
molecule 1 (ICAM-1), which facilitates transmigration of
leukocytes across vascular endothelia in processes such as
extravasation and the inflammatory response, was associated
with recurrence in multivariate analysis [60]. The biomarker
value of these molecules warrants further studies in order to
evaluate its role in BCG immunotherapy response.
Eﬀorts were made in order to find serological predictive
markers of BCG treatment outcome. Molecules such as
purified protein derivative (PPD), HSP65/70, major secreted
antigen complex (Ag85), immunogenic, and skin-reactive
protein, p64, have been explored [70–72]. Still, the serologi-
cal levels of these proteins were not able to predict BCG treat-
ment failure [70–72]. Also, several immunological mediators
were evaluated in blood of BCG-treated patients, but none
was associated with recurrence after BCG treatment with the
exception that lower levels of IL-2 appear to be associated
with recurrence [70, 71]. Therefore, with the exception of
IL-2, molecules found in the peripheral circulation may not
be a suitable approach to find predictive biomarkers of BCG
response.
3.3. Genetic Polymorphisms
3.3.1. NRAMP1(SLC11A1) Gene. Natural resistance-associ-
ated macrophage protein 1 (NRAMP1) gene regulates intra-
cellular pathogen proliferation and macrophage inflamma-
tory responses. NRAMP1 is one of the most studied genes,
with 5 polymorphisms analyzed in 2 papers [73, 74]. Chiong
et al.(2010) [73] found that (GT)n repeat and D543N GA
genotype were associated with reduced RFS, this author also
studied hGPX1 gene, and an association was found [73]. On
the other hand, Decobert in 2006 [74] found that D543N GG
genotype is also associated with reduced time to recurrence.
3.3.2. DNA Repair Genes. Gu et al. (2005) [75] analyzed sev-
eral polymorphisms in XPA, XPC, XPD, XPG, ERCC1, and
ERCC6 genes and found that XPA 5′UTR AA was correlated
with higher RFS when compared with AG andGG genotypes,
and ERCC6 Met1097Val GG genotype was associated with
reduced RFS after BCG treatment [75]. However, Gangwar
and colleagues (2010) [76] have also studied XPC gene
polymorphisms and found that patients carrying AC or
CC genotypes of XPC Lys939Gln have reduced RFS [76].
The same author published other paper in 2010 regarding
polymorphisms in APEX1 and ERCC2 genes and found that
ERCC2 Asp312Asn AA was also associated with reduced
RFS [77]. Polymorphisms in XRCC1/3/4 genes were also
studied, only XRCC1 codon11 AA genotype was associated
with reduced RFS after BCG treatment [78, 79].
3.3.3. Inflammation-associated Genes. Rama Mittal group
has published several studies [80–83] regarding several poly-
morphisms in inflammatory genes such as IFNG, TNFA,
TGFB1, COX2, PPARG, IL1B, IL1RN, IL4, IL6, and IL8 [80,
81, 83–85]. They found that IL8-251 AA, TNFA-1031 CC,
IL6-174 CC, and TGFB1+28 TT genotypes were associated
with higher RFS after BCG treatment [80, 81, 84, 85]. On the
other hand, they found that patients carrying COX2-765CC
genotype or NFKB ATTG Del/Del genotypes or IFNA LOH
or IFNG+874 A allele have a decreased RFS after treatment.
Considering the IL6-174 G/C, Leibovici et al.(2005) [86]
found conflicting results in which CC genotype was associ-
ated with a reduced RFS after BCG. Other paper (not shown
in Table 3) evaluated the influence 22 polymorphisms in 13
inflammatory genes on recurrence after BCG treatment [87];
patients carrying theTGFB codon 10 T allele,TGFB codon 25
G allele, IL4-1098GG genotype, and IL10-1082GG genotype
are at higher risk of recurrence after BCG treatment [87].
3.3.4. Cell Cycle and Apoptosis Genes. The role of genetic
polymorphisms on genes such as MMP1/2/3/7/8/9, FAS,
CASP8/9, MDM2, and CCDN1 on BCG treatment outcome
was addressed by some authors [88–92]. It was found
that patients carrying MMP2-1306 T allele or MMP3-1171
5A/6A have a reduced RFS after treatment [91, 92] and
patients carrying MMP1-1607 1G/2G or CASP9-1263 GG or
MDM2+309GG genotypes have an increased RFS [88–90].
3.3.5. Sonic Hedgehog Pathway Genes. A recent paper evalu-
ated 177 polymorphisms (haplotype tag SNPs) in 11 genes
on Sonic Hedgehog Pathway (Shh) [93]. The main result
regarding BCG-treated patients shows that 2 polymorphisms
in GLI3 gene (rs6463089 and rs3801192) were associated
with worse treatment outcome [93]. Patients carrying at least
on variant allele of these SNPs have a decreased RFS when
compared with wild-type carriers [93].
4. Discussion
Several studies were conducted to personalize and improve
the NMIBC treatment with BCG. A plethora of exciting data
has emerged recently, which represents a potential tool to
define diﬀerences in BCG treatment response.
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Among the proteins associated with bladder cancer
progression, p53 and ki67 are the most well studied. Still,
the evaluation of these markers in the context of BCG
treatment did not oﬀer strong evidences regarding their role
as predictive biomarkers.
Conversely, CD68 has shown a huge potential as a pre-
dictive biomarker. Indeed, tumour-associated macrophages
(TAMs), when detected at tumour core and surrounding
tissue, strongly correlated with tumour treatment response
[41, 42]. It has been suggested that a higher number of TAMs
can promote a more eﬃcient phagocytosis and elimination
of BCG, preventing BCG from inducing a long-term local
inflammation [41]. Although the results regarding this
marker are consistent, complementary information are still
necessary to confirm the predictive value of these marker and
the influence of TAMs presence in the treatment outcome.
Namely, it will be important to verify the phenotypic nature
of this TAMS, as only the M2 macrophages are known to
produce protumor factors such as inflammatory cytokines
that could inhibit BCG treatment response [40].
Tumour markers like ezrin, HSP90, CD83, and others
also reveal a potential as biomarkers of BCG treatment res-
ponse. However, only one paper addresses these biomarkers
in the context of BCG treatment outcome. In this sense, more
studies are needed to validate if these markers are suitable
candidates to predict BCG treatment outcome.
Urinary markers are widely studied worldwide, and
several molecules, such as IL-8, IL-2, and, in a lesser extent,
TNF-α and IL-18, are currently believed to play a role on
BCG immunotherapy mechanism of action. More impor-
tantly, their levels have appeared to be associated with
treatment failure. However, as state by Zuiverloon et al. [94],
these markers are “during BCG markers,” only present in
urine during the course of treatment, thus failing to provide
insight on the outcome prior to that. pm Nonetheless, the
role of urine in noninvasive approaches to monitor response
has been demonstrated.
Pharmacogenomic investigation has also demonstrated
to be a powerful tool in the identification of predic-
tive biomarkers. Regarding BCG immunotherapy, several
polymorphisms in a large set of genes have demonstrated
the potential to predict treatment outcome. Polymorphism
in inflammatory genes such as IL8, TNFA, IL6, TGFB1,
COX2, and IFNG are examples of putative predictive markers
[80, 81, 83–85].
However most of them were studied in the same Indian
population which was small in number (80 patients).
Moreover, the majority of these patients have been subjected
only to a induction schedule with BCG (iBCG) [76–81, 83–
85, 88–92]. In order to be used as a predictive markers,it is
still necessary to evaluate these polymorphism in larger sets
of patients, with a representative number of patients treated
with a full maintenance BCG treatment schedule (mBCG)
and from other ethnicities. Furthermore, there are several
other molecules involved in BCG immunotherapy mecha-
nism of action and potentially involved in the treatment
response that may be subjected to polymorphism analysis.
In a recent review, Alexandroﬀ and colleagues suggest
that molecules such as IL-2, IL-17, IL-23, soluble CD40L,
and TRAIL may be important key targets and may serve
as putative markers [16]. A careful evaluation of such
candidates should be undertaken in order to access their
biomarker value.
Recently, the studies by Kim and colleagues [51] using a
microarray analysis allowed to identify a “poor predictive sig-
nature” of BCG treatment response. This work is suggesting
that a combinatory analysis involving all predictive markers
may permit to create a useful score or a predictive profile. The
combination of several markers will allow explaining and
consequently predicting all recurrences after BCG treatment.
Other current approaches, such as microRNAs profiling and
Genome wide association studies (GWAS) can be important
features in the context of BCG immunotherapy research and
treatment response prediction.
5. Conclusion
Regarding the tumour molecular characteristics studied,
three major conclusions can be drawn, p53 and ki-67 are
not suitable predictive biomarkers, markers such as TAMs
and other molecules (ezrin, HSP90, CD83, and Cox2)
require validation, and diﬀerent approaches such as gene
expression and epigenetic alterations of the tumour prior to
treatment may bring new insights in the search for predictive
biomarkers of BCG immunotherapy.
Concerning urinary markers, the monitoring of IL-
2 levels during treatment seems a consistent noninvasive
approach to determine treatment response; hence, other
cytokines could have the same predictive power. The only
drawback is the fact that these markers are unable to
predictive treatment response prior to therapy.
In relation to genetic polymorphisms, those in the genes
IL8, TNFA, IL6, TGFB1, COX2, and IFNG were found to be
among the most informative. Nevertheless, it is important
to validate the findings in larger samples from diﬀerent
ethnicities and evaluate other genetic polymorphism in
molecules that have shown to have a important role in BCG
immunotherapymechanism of action (e.g., IL-2, TRAIL, and
Th17 cytokines).
It is our belief that only the introduction of an array of
biomarkers can improve the accuracy of current status on the
prediction of BCG treatment outcome and thus improve the
management of high-risk NMIBC. Future studies combining
the most promising putative biomarkers are warranted if not
mandatory.
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